- Home
- HSII vs ANAB Comparison
HSII vs ANAB Comparison
Compare HSII & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- ANAB
- Stock Information
- Founded
- HSII 1953
- ANAB 2005
- Country
- HSII United States
- ANAB United States
- Employees
- HSII N/A
- ANAB N/A
- Industry
- HSII Diversified Commercial Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- ANAB Health Care
- Exchange
- HSII Nasdaq
- ANAB Nasdaq
- Market Cap
- HSII 904.3M
- ANAB 759.5M
- IPO Year
- HSII 1999
- ANAB 2017
- Fundamental
- Price
- HSII $37.96
- ANAB $20.55
- Analyst Decision
- HSII Buy
- ANAB Buy
- Analyst Count
- HSII 2
- ANAB 10
- Target Price
- HSII $48.00
- ANAB $36.38
- AVG Volume (30 Days)
- HSII 164.2K
- ANAB 1.0M
- Earning Date
- HSII 05-05-2025
- ANAB 05-08-2025
- Dividend Yield
- HSII 1.58%
- ANAB N/A
- EPS Growth
- HSII N/A
- ANAB N/A
- EPS
- HSII 0.41
- ANAB N/A
- Revenue
- HSII $1,098,573,000.00
- ANAB $91,280,000.00
- Revenue This Year
- HSII $5.41
- ANAB N/A
- Revenue Next Year
- HSII $3.97
- ANAB $37.76
- P/E Ratio
- HSII $92.59
- ANAB N/A
- Revenue Growth
- HSII 6.98
- ANAB 432.03
- 52 Week Low
- HSII $29.03
- ANAB $12.21
- 52 Week High
- HSII $49.02
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- HSII 34.94
- ANAB 65.12
- Support Level
- HSII $37.69
- ANAB $15.40
- Resistance Level
- HSII $42.17
- ANAB $19.82
- Average True Range (ATR)
- HSII 1.87
- ANAB 1.49
- MACD
- HSII -0.32
- ANAB 0.16
- Stochastic Oscillator
- HSII 4.49
- ANAB 96.26
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).